Details for Patent: 10,973,836

Which drugs does patent 10,973,836 protect, and when does it expire?

Patent 10,973,836 protects FARXIGA and is included in one NDA.

Protection for FARXIGA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in nineteen countries.

Summary for Patent: 10,973,836

Title:	Methods of treating heart failure with reduced ejection fraction
Abstract:	The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.
Inventor(s):	Anna Maria LANGKILDE
Assignee:	AstraZeneca AB
Application Number:	US16/812,745
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,973,836

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	10,973,836*PED				Y

International Family Members for US Patent 10,973,836

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	118963
Australia	2020202887
Australia	2021215150